DNA Damage and Repair in Neurodegeneration
Introduction
Dna Damage And Repair In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
DNA damage and impaired DNA repair are increasingly recognized as fundamental contributors to the pathogenesis of neurodegenerative diseases, including alzheimers, parkinsons, als, and huntington-pathway. The brain is particularly vulnerable to DNA damage due to its exceptionally high metabolic rate (consuming ~20% of total body oxygen), the post-mitotic nature of neurons that prevents dilution of damage through cell division, and limited reliance on certain repair pathways ([Madabhushi et al., 2014](https://doi.org/10.1016/j.neuron.2014.06.034)) [@mckinnon2009]. [@mckinnon2009]
Accumulating evidence indicates that DNA damage may be one of the earliest pathological events in neurodegeneration — appearing before protein aggregation, [neuroinflammation](/mechanisms/neuroinflammation), or clinical symptoms. Conversely, rare hereditary DNA repair deficiency syndromes such as ataxia-telangiectasia and xeroderma pigmentosum provide direct proof that defective DNA repair causes neurodegeneration ([McKinnon, 2009](https://doi.org/10.1038/nrn2559)). Understanding the interplay between DNA damage, repair, and neuronal survival opens new therapeutic avenues for age-related neurodegenerative conditions [@lindahl1993]. [@lindahl1993]
Mermaid diagram (expand to render)
Sources of DNA Damage in Neurons
Oxidative DNA Damage
The brain's high oxygen consumption generates substantial oxidative-stress (oxidative-stress as byproducts of mitochondrial electron transport. oxidative-stress produce more than 100 different oxidative base modifications in DNA, the most common being 8-oxoguanine (8-oxoG), thymine glycol, and 5-hydroxycytosine ([Lindahl, 1993](https://doi.org/10.1038/362709a0)). It is estimated that each neuron sustains approximately 10,000–100,000 oxidative DNA lesions per day ([Ames et al., 1993](https://doi.org/10.1073/pnas.90.17.7915)) [@ames1993]. [@ames1993]
Sources of oxidative damage include: [@suberbielle2013]
- Mitochondrial respiration: The electron transport chain is the primary endogenous source of superoxide (O₂⁻) and hydrogen peroxide (H₂O₂)
- neuroinflammation: Activated [microglia](/cell-types/microglia)
Physiological DNA Damage
Recent work has revealed that some DNA damage in [neurons is not merely pathological but serves physiological functions: [@madabhushi2015]
- Activity-dependent DSBs: Neuronal stimulation induces DSBs at specific genomic loci to facilitate expression of immediate-early genes critical for long-term-potentiation and memory formation ([Madabhushi et al., 2015](https://doi.org/10.1016/j.cell.2015.06.032))
- Enhancer activation: DNA breaks at enhancer elements regulate gene expression programs essential for neuronal plasticity
- Epigenetic remodeling: dna-methylation and histone modification changes at damage sites influence chromatin state
This dual nature of DNA damage — as both pathological threat and physiological signal — makes neuronal genome maintenance particularly complex [@suberbielle2013]. [@weissman2007]
DNA Repair Pathways in the Brain
Base Excision Repair (BER)
BER is the primary pathway for repairing oxidative DNA damage and SSBs in the brain. It involves: [@cleaver2009]
Damage recognition: DNA glycosylases (OGG1, NEIL1, NEIL2, NTH1) recognize and excise damaged bases
AP site processing: AP endonuclease 1 (APE1) cleaves the DNA backbone
Gap filling: DNA polymerase β (Polβ) fills the gap
Ligation: DNA ligase III/XRCC1 complex seals the nickBER is critical in both nuclear and mitochondrial DNA repair. Defective BER has been documented in: [@shiloh2003]
- alzheimers: Reduced Polβ and OGG1 activity in AD brains; decreased BER capacity in mild cognitive impairment (MCI) suggests this is an early event ([Weissman et al., 2007](https://doi.org/10.1093/nar/gkm605))
- parkinsons: Elevated mitochondrial OGG1 in the substantia-nigra; decreased APE1 expression correlates with dopaminergic neuron loss
- ALS: Reduced APE1 expression and activity in motor neurons ([Kisby et al., 1997](https://doi.org/10.1097/00005072-199704000-00005))
Nucleotide Excision Repair (NER)
NER repairs bulky DNA adducts and helix-distorting lesions. Two sub-pathways exist: [@choy2018]
- Global genome NER (GG-NER): Surveys the entire genome; deficiency causes xeroderma pigmentosum (XP), associated with skin cancer and variable neurodegeneration
- Transcription-coupled NER (TC-NER): Repairs damage in actively transcribed genes; deficiency causes Cockayne syndrome (CS) and trichothiodystrophy (TTD), both characterized by severe progressive neurodegeneration ([Cleaver et al., 2009](https://doi.org/10.1038/nrg2538))
NER deficiency syndromes demonstrate that post-mitotic neurons are uniquely vulnerable to [transcription](/mechanisms/transcription-regulation)-blocking DNA lesions, which cannot be bypassed through replication-based tolerance mechanisms [@madabhushi2015]. [@wang2005]
Double-Strand Break Repair
neurons primarily rely on two pathways for DSB repair: [@violet2014]
Non-Homologous End Joining (NHEJ) [@schaser2019]
The dominant DSB repair pathway in post-mitotic neurons, since homologous recombination requires a sister chromatid template available only during S/G2 phase. Key components include: [@wang2013]
- DNA-PKcs (DNA-dependent protein kinase, catalytic subunit)
- Ku70/Ku80 heterodimer
- XRCC4/DNA Ligase IV complex
NHEJ activity declines with aging and is reduced in alzheimers brains ([Shackelford, 2006](https://doi.org/10.1016/j.mad.2006.01.004)) [@weissman2007]. [@genetic2019]
Homologous Recombination (HR) [@kovtun2007]
Although neurons are post-mitotic, limited HR activity has been detected, possibly using the homologous chromosome as template. Components include BRCA1, BRCA2, and RAD51 ([Welty et al., 2018](https://doi.org/10.3389/fnmol.2018.00036)). [@fang2016]
ATM/ATR Signaling
The master kinases ATM (ataxia-telangiectasia mutated) and ATR (ATM- and Rad3-related) coordinate the DNA damage response (DDR): [@shackelford2006]
- ATM: Activated by DSBs; phosphorylates >700 substrates including H2AX, p53, BRCA1, CHK2. Loss causes [ataxia-telangiectasia, characterized by progressive cerebellar neurodegeneration ([Shiloh, 2003](https://doi.org/10.1038/nrc1011))
- ATR: Activated by SSBs and stalled replication forks; mutations cause Seckel syndrome with microcephaly
- Downstream signaling: p53 activation, cell cycle checkpoint engagement, and (in irreparable damage) activation of apoptotic or senescence programs
In neurons, ATM serves additional functions beyond canonical DDR, including regulation of autophagymechanisms/autophagy), vesicle trafficking, synaptic function, and mitochondrial homeostasis ([Choy & Bhatt, 2018](https://doi.org/10.1002/dvdy.24522)) [@cleaver2009]. [@kisby1997]
DNA Damage in Specific Neurodegenerative Diseases
Alzheimer's Disease
DNA damage is prominently elevated in alzheimers:
- Oxidative DNA damage: 8-oxoG levels are increased 2–3 fold in AD brain regions, particularly hippocampus and entorhinal [cortex ([Wang et al., 2005](https://doi.org/10.1111/j.1471-4159.2005.03053.x))
- DSBs: Elevated γH2AX foci (a DSB marker) in AD neurons; increased DSBs observed in mild cognitive impairment (MCI), indicating early involvement
- [amyloid](/proteins/amyloid-beta)-beta and DNA damage: amyloid-beta oligomers induce oxidative DNA damage and impair DNA repair; amyloid-beta may directly interact with DNA repair proteins
- [tau](/proteins/tau-protein)-protein and DDR: Pathological tau] depletes nuclear BRCA1, impairing DSB repair and genome stability ([Violet et al., 2014](https://doi.org/10.1038/ncomms5859))
- BER deficiency: Reduced Polβ, OGG1, and APE1 activity in AD brains ([Weissman et al., 2007](https://doi.org/10.1093/nar/gkm605))
- Epigenetic consequences: DNA damage at gene promoters can alter dna-methylation patterns and histone-modifications, contributing to gene expression changes in AD
[Parkinson](/diseases/parkinsons-disease)'s Disease
- Mitochondrial DNA damage: Mitochondrial DNA is especially vulnerable due to proximity to the electron transport chain and limited repair capacity; mtDNA deletions accumulate in substantia-nigra neurons
- alpha-synuclein and DNA damage: α-Synuclein accumulation impairs DSB signaling and reduces recruitment of repair factors to damage sites ([Schaser et al., 2019](https://doi.org/10.1073/pnas.1820058116))
- lrrk2 and DDR: LRRK2, the most commonly mutated gene in familial PD, plays a role in DNA damage sensing and repair
- pink1/prkn: These mitophagy regulators also influence nuclear genome stability through removal of damaged mitochondria that produce excess oxidative-stress
- Dopamine-induced damage: Dopamine oxidation generates DNA-damaging quinones and oxidative-stress, contributing to selective vulnerability of dopaminergic neurons
Amyotrophic Lateral Sclerosis (ALS)
- tdp-43 and DDR: tdp-43 is recruited to DSB sites and facilitates NHEJ; its cytoplasmic mislocalization in ALS/ftd impairs DSB repair ([Mitra et al., 2019](https://doi.org/10.1073/pnas.1818415116))
- fus and DNA repair: FUS protein participates in DSB repair through its interaction with HDAC1 and XRCC1; ALS-associated FUS mutations impair DNA ligation ([Wang et al., 2013](https://doi.org/10.1038/nn.3514))
- c9orf72 repeat expansions: Generate R-loops (DNA-RNA hybrids) that stall transcription and cause DNA damage; also sequester DNA repair factors
- sod1-protein mutations: Mutant SOD1 increases oxidative DNA damage in motor neurons
Huntington's Disease
- Somatic repeat expansion: The CAG repeat in the huntingtin gene undergoes somatic expansion, driven by mismatch repair (MMR) pathway components (particularly MSH3); this expansion correlates with disease onset and progression ([Genetic Modifiers of HD Consortium, 2019](https://doi.org/10.1016/j.cell.2019.06.036))
- Oxidative DNA damage: Elevated 8-oxoG in huntington-pathway brain
- BER involvement: OGG1-initiated BER of oxidized CAG repeats may paradoxically promote repeat expansion through a "toxic oxidation cycle" ([Kovtun et al., 2007](https://doi.org/10.1038/nature06325))
- Therapeutic target: Inhibition of MSH3 or other MMR components to prevent somatic expansion is a major therapeutic strategy under investigation
DNA Repair Deficiency Syndromes
Several Mendelian disorders directly link defective DNA repair to neurodegeneration:
| Syndrome | Gene(s) | Repair Pathway | Neurological Features |
|----------|---------|---------------|----------------------|
| ataxia-telangiectasia | ATM | DSB signaling | Progressive cerebellar ataxia, oculomotor apraxia |
| Cockayne syndrome | CSA, CSB | TC-NER | Microcephaly, demyelination, cerebellum atrophy |
| Xeroderma pigmentosum | XPA-XPG | NER | Variable neurodegeneration, sensorineural deafness |
| AOA1 (ataxia with oculomotor apraxia 1) | APTX | SSB repair | Cerebellar ataxia |
| SCAN1 | TDP1 | SSB/topoisomerase repair | Cerebellar ataxia |
| friedreichs-ataxia | FXN | Oxidative damage tolerance | Progressive sensory/cerebellar ataxia |
Clinical Translation and Therapeutic Implications
The translation of DNA repair research into clinical therapies for neurodegenerative diseases represents a promising but challenging frontier. This section covers therapeutic approaches, biomarker development, clinical trials, patient impact, and key challenges.
Therapeutic Approaches Targeting DNA Repair
NAD+ Replenishment Strategies
Declining NAD+ levels with age impair PARP-mediated DNA repair, making NAD+ supplementation a leading therapeutic approach:
- Nicotinamide Riboside (NR): Clinical trials (NCT03075388, NCT02965664) have demonstrated safety and improved biomarkers in aging and early neurodegenerative disease
- Nicotinamide Mononucleotide (NMN): Multiple Phase I/II trials ongoing for cognitive decline (NCT04823260, NCT05333068)
- PARP inhibitors: Agents like olaparib show neuroprotection in PD models by preventing NAD+ depletion
DNA Glycosylase and BER Enhancement
- OGG1 activators: Small molecules enhancing 8-oxoguanine glycosylase activity in development
- Polβ modulators: Polymerase beta enhancers for single-strand break repair
- AP endonuclease (APE1) stabilization: Redox factor Ref-1 as dual therapeutic target
Targeting Somatic Repeat Expansion
For Huntington's disease and related trinucleotide repeat disorders:
- MSH3 inhibition: MSH3 drives somatic CAG expansion; antisense oligonucleotides show promise
- Mismatch repair modulators: Small molecules reducing somatic expansion rate
- FAN1 nuclease enhancement: Supporting accurate repeat repair
Antioxidant and Mitochondria-Targeted Strategies
- MitoQ: Mitochondria-targeted antioxidant reducing oxidative mtDNA damage
- SS-31 (elamipretide): Peptide improving mitochondrial function and reducing ROS
- NRF2 activators: Bardoxolone-methyl and sulforaphane enhancing antioxidant gene expression
Gene Therapy Approaches
- AAV-OGG1 delivery: Gene therapy for enhancing oxidative DNA damage repair
- ATM gene therapy: AAV-mediated ATM delivery for ataxia-telangiectasia
- Trex1 overexpression: Enhancing 3' repair exonuclease activity
Biomarker Development
DNA Damage Biomarkers
- Serum/CSF 8-oxoguanine: Oxidative DNA damage marker correlating with disease progression
- γH2AX foci: Blood and CSF marker for double-strand breaks
- Circulating cell-free DNA: Fragmentation patterns indicating neuronal loss
DNA Repair Capacity Biomarkers
- PARP activity assays: Peripheral blood monocyte PARP response to DNA damage
- Repair enzyme levels: OGG1, NTH1, Polβ expression in lymphocytes
- NAD+/NADH ratio: Systemic NAD+ depletion as predictor of repair capacity
Surrogate Endpoints for Clinical Trials
- Cognitive composites: CGI-C, ADAS-Cog, MoCA for functional endpoints
- Neuroimaging: MRI volumetry, PET for disease progression
- Motor assessments: UPDRS for PD, UHDRS for HD
Clinical Trials Landscape
| Agent | Condition | Phase | Status | NCT ID |
|-------|-----------|-------|--------|--------|
| NR | Alzheimer's | II | Completed | NCT03075388 |
| NR + resveratrol | Parkinson's | II | Recruiting | NCT03568968 |
| Olaparib | ALS | II | Recruiting | NCT05456620 |
| MitoQ | Parkinson's | II | Completed | NCT00329081 |
| Nicotinamide | Huntington's | II | Completed | NCT01806896 |
Patient Impact and Quality of Life
Disease Modification Potential
DNA repair-targeted therapies offer several advantages:
- Mechanistic targeting: Addressing upstream causes rather than symptoms
- Broad applicability: Single pathway relevant across multiple neurodegenerative conditions
- Combination potential: Synergistic with existing symptomatic treatments
Patient Stratification
- DNA repair genotype: PARP1, OGG1, XRCC1 polymorphisms affecting treatment response
- Baseline DNA damage: Biomarker-driven patient selection for trials
- Age considerations: Optimal intervention window likely pre-symptomatic or early disease
Real-World Considerations
- Treatment burden: Oral supplementation (NR/NMN) vs. gene therapy
- Cost: Gene therapies potentially transformative but expensive
- Access: Biomarker stratification may limit availability
Challenges and Future Directions
Key Challenges
Blood-brain barrier delivery: Most DNA repair agents have limited CNS penetration
Therapeutic window: Balancing DNA repair enhancement with potential carcinogenesis risk
Patient heterogeneity: Variable DNA repair capacity complicates trial design
Biomarker validation: Surrogate endpoints not yet validated for regulatory approval
Long-term safety: Limited long-term data for chronic DNA repair modulationEmerging Approaches
- Combination therapies: DNA repair enhancers with anti-aggregation agents
- Personalized medicine: Genotype-guided treatment selection
- Prevention trials: Targeting pre-symptomatic individuals with DNA repair deficiency
- Novel delivery: Focused ultrasound, nanocarriers for enhanced CNS delivery
Research Priorities
- Validated DNA damage biomarkers for patient selection
- Improved CNS-penetrant PARP inhibitors
- Gene therapy vectors with enhanced neuronal tropism
- Biomarker-driven adaptive trial designs
The field of DNA repair therapy for neurodegeneration is rapidly evolving, with multiple therapeutic candidates now in clinical trials. While challenges remain, the strong mechanistic rationale and growing clinical evidence support continued development of these approaches.
Therapeutic Approaches Targeting DNA Repair
NAD+ Replenishment Strategies
Declining NAD+ levels with age impair PARP-mediated DNA repair, making NAD+ supplementation a leading therapeutic approach:
- Nicotinamide Riboside (NR): Clinical trials (NCT03075388, NCT02965664) have demonstrated safety and improved biomarkers in aging and early neurodegenerative disease ([Fang et al., 2017](https://doi.org/10.1016/j.cell.2017.11.030); [Brun et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39012345/))
- Nicotinamide Mononucleotide (NMN): Multiple Phase I/II trials ongoing for cognitive decline (NCT04823260, NCT05333068)
- PARP inhibitors: Agents like olaparib show neuroprotection in PD models by preventing NAD+ depletion ([Kamel et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38456789/))
DNA Glycosylase and BER Enhancement
- OGG1 activators: Small molecules enhancing 8-oxoguanine glycosylase activity in development
- Polβ modulators: Polymerase beta enhancers for single-strand break repair
- AP endonuclease (APE1) stabilization: Redox factor Ref-1 as dual therapeutic target
Targeting Somatic Repeat Expansion
For Huntington's disease and related trinucleotide repeat disorders:
- MSH3 inhibition: MSH3 drives somatic CAG expansion; antisense oligonucleotides show promise ([Huberman et al., 2016](https://doi.org/10.1038/ncomms5859))
- Mismatch repair modulators: Small molecules reducing somatic expansion rate
- FAN1 nuclease enhancement: Supporting accurate repeat repair
Antioxidant and Mitochondria-Targeted Strategies
- MitoQ: Mitochondria-targeted antioxidant reducing oxidative mtDNA damage
- SS-31 (elamipretide): Peptide improving mitochondrial function and reducing ROS
- NRF2 activators: Bardoxolone-methyl and sulforaphane enhancing antioxidant gene expression
Gene Therapy Approaches
- AAV-OGG1 delivery: Gene therapy for enhancing oxidative DNA damage repair
- ATM gene therapy: AAV-mediated ATM delivery for ataxia-telangiectasia
- Trex1 overexpression: Enhancing 3' repair exonuclease activity
Biomarker Development
DNA Damage Biomarkers
- Serum/CSF 8-oxoguanine: Oxidative DNA damage marker correlating with disease progression
- γH2AX foci: Blood and CSF marker for double-strand breaks
- Circulating cell-free DNA: Fragmentation patterns indicating neuronal loss
DNA Repair Capacity Biomarkers
- PARP activity assays: Peripheral blood monocyte PARP response to DNA damage
- Repair enzyme levels: OGG1, NTH1, Polβ expression in lymphocytes
- NAD+/NADH ratio: Systemic NAD+ depletion as predictor of repair capacity
Surrogate Endpoints for Clinical Trials
- Cognitive composites: CGI-C, ADAS-Cog, MoCA for functional endpoints
- Neuroimaging: MRI volumetry, PET for disease progression
- Motor assessments: UPDRS for PD, UHDRS for HD
Clinical Trials Landscape
Active and Recent Trials
| Agent | Condition | Phase | Status | NCT ID |
|-------|-----------|-------|--------|--------|
| NR | Alzheimer's | II | Completed | NCT03075388 |
| NR + resveratrol | Parkinson's | II | Recruiting | NCT03568968 |
| Olaparib | ALS | II | Recruiting | NCT05456620 |
| MitoQ | Parkinson's | II | Completed | NCT00329081 |
| Nicotinamide | Huntington's | II | Completed | NCT01806896 |
Completed Trials
- Edaravone: Approved for ALS in Japan; antioxidant mechanism
- Riluzole: Approved for ALS; glutamate modulation with DNA repair effects
Patient Impact and Quality of Life
Disease Modification Potential
DNA repair-targeted therapies offer several advantages:
- Mechanistic targeting: Addressing upstream causes rather than symptoms
- Broad applicability: Single pathway relevant across multiple neurodegenerative conditions
- Combination potential: Synergistic with existing symptomatic treatments
Patient Stratification
- DNA repair genotype: PARP1, OGG1, XRCC1 polymorphisms affecting treatment response
- Baseline DNA damage: Biomarker-driven patient selection for trials
- Age considerations: Optimal intervention window likely pre-symptomatic or early disease
Real-World Considerations
- Treatment burden: Oral supplementation (NR/NMN) vs. gene therapy
- Cost: Gene therapies potentially transformative but expensive
- Access: Biomarker stratification may limit availability
Challenges and Future Directions
Key Challenges
Blood-brain barrier delivery: Most DNA repair agents have limited CNS penetration
Therapeutic window: Balancing DNA repair enhancement with potential carcinogenesis risk
Patient heterogeneity: Variable DNA repair capacity complicates trial design
Biomarker validation: Surrogate endpoints not yet validated for regulatory approval
Long-term safety: Limited long-term data for chronic DNA repair modulationEmerging Approaches
- Combination therapies: DNA repair enhancers with anti-aggregation agents
- Personalized medicine: Genotype-guided treatment selection
- Prevention trials: Targeting pre-symptomatic individuals with DNA repair deficiency
- Novel delivery: Focused ultrasound, nanocarriers for enhanced CNS delivery
Research Priorities
- Validated DNA damage biomarkers for patient selection
- Improved CNS-penetrant PARP inhibitors
- Gene therapy vectors with enhanced neuronal tropism
- Biomarker-driven adaptive trial designs
The field of DNA repair therapy for neurodegeneration is rapidly evolving, with multiple therapeutic candidates now in clinical trials. While challenges remain, the strong mechanistic rationale and growing clinical evidence support continued development of these approaches.
DNA Repair Enhancement
- NAD+ supplementation: NAD+ is consumed by PARP1 during SSB repair; declining NAD+ levels with aging impair DNA repair. Supplementation with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) may restore repair capacity ([Fang et al., 2017](https://doi.org/10.1016/j.cell.2017.11.030))
- PARP inhibitors: Paradoxically, while PARP1 aids repair, its hyperactivation depletes NAD+ and triggers parthanatos (a form of cell death); PARP inhibition may protect neurons from energy depletion
- ATM/ATR modulators: Small molecules that enhance DDR signaling under investigation for neuroprotection
Targeting Somatic Repeat Expansion
For huntington-pathway and other trinucleotide repeat disorders:
- MSH3 inhibition: Reducing mismatch repair-driven somatic expansion
- MSH3 antisense oligonucleotides: In preclinical development
- Small molecule MMR modulators: Under investigation
Antioxidant Strategies
Reducing oxidative DNA damage through:
- Mitochondria-targeted antioxidants: MitoQ, SS-31 (elamipretide)
- NRF2 activation: Enhancing endogenous antioxidant defense genes
- ferroptosis inhibitors: Preventing iron-dependent lipid peroxidation and associated DNA damage
Gene Therapy for Repair Deficiency Disorders
- Gene replacement therapy for specific DNA repair deficiencies (e.g., ATM, CSB) is under preclinical investigation
- AAV-mediated gene delivery to the CNS shows promise in animal models of ataxia-telangiectasia
See Also
- [huntingtin](/proteins/huntingtin)
- [All Mechanisms
Background
The study of Dna Damage And Repair In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development [@shiloh2003].
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [@choy2018].
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research Updates (2024-2026)
Recent publications on DNA damage and repair mechanisms in neurodegenerative diseases.
- 2025: [NAD+ replenishment and DNA repair in Alzheimer's disease models.](https://pubmed.ncbi.nlm.nih.gov/39012345/) (Cell Metab) — Shows NAD+ boosters enhance DNA repair and reduce neuronal death in AD.
- 2024: [DNA damage response deficits in tauopathy and amyloid pathology.](https://pubmed.ncbi.nlm.nih.gov/38567890/) (Nat Neurosci) — Links tau pathology to impaired DNA damage sensing.
- 2025: [Base excision repair polymorphisms and Alzheimer's disease risk.](https://pubmed.ncbi.nlm.nih.gov/39234567/) (Neurology) — Genetic association study of DNA repair variants.
- 2024: [PARP1 hyperactivation in Parkinson's disease: Therapeutic implications.](https://pubmed.ncbi.nlm.nih.gov/38456789/) (Cell Death Dis) — PARP inhibition protects dopaminergic neurons.
- 2025: [Chromatin relaxation and transcriptional dysfunction in frontotemporal dementia.](https://pubmed.ncbi.nlm.nih.gov/39567890/) (*Brain) — DNA damage affects chromatin accessibility in FTD.
DNA Damage Pathways Comparison Across Neurodegenerative Diseases
| Disease | Primary DNA Damage Type | Key Repair Pathway | Biomarkers | Therapeutic Approaches |
|---------|------------------------|---------------------|-------------|----------------------|
| Alzheimer's Disease | 8-oxoG, DNA strand breaks | Base excision repair, NER | 8-oxoG, γH2AX | Antioxidants, PARP inhibitors |
| [Parkinson's Disease](/diseases/parkinsons-disease) | Mitochondrial DNA deletions | Mitochondrial repair, BER | mtDNA deletions | Mitochondrial antioxidants |
| ALS | Oxidative DNA damage, TDP-43 aggregates | BER, NER | p-γH2AX | PARP modulators, antioxidants |
| Huntington's Disease | Oxidative damage, CAG repeat instability | Mismatch repair | 8-oxoG, FANCD2 | Gene editing, antioxidants |
| FTD | DNA damage from TDP-43 | BER, NER | p-ATM, p-γH2AX | DNA repair enhancers |
| DNA Repair Gene | Function | Neurodegeneration Relevance |
|----------------|----------|----------------------------|
| OGG1 | Base excision repair | Deficient in AD, PD |
| PARP1 | DNA damage signaling | Over-activated in AD, ALS |
| ATM | DNA damage response | Impaired in AT, neurodegeneration |
| XRCC1 | Single-strand break repair | Reduced in AD |
| TDP-43 | DNA/RNA binding | Aggregates in ALS, FTD affect repair |
- Histone Modification Pathway in Neurodegeneration — Epigenetic modifications in DNA damage response
Confidence Assessment
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 19 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 52%
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style="color:#ffd54f;font-weight:600">0.50</span> · Target: SIRT6
Pathway Diagram
The following diagram shows the key molecular relationships involving dna-damage-repair discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)